Abstract
Background Inflammatory bowel disease (IBD) is an established risk factor for colorectal cancer. Recent reports suggesting IBD is also a risk factor for prostate cancer (PC) require further investigation.
Objective To test the association between IBD with incident PC.
Design, setting, and participants We studied 218,084 men in the population-based UK Biobank cohort, aged 40-69 at study entry between 2006 and 2010, with follow-up through mid-2015.
Outcome measurements and statistical analysis We assessed the association between IBD and subsequent PC using multivariable Cox regression analyses, adjusting for age at assessment, ethnic group, UK region, smoking status, alcohol drinking frequency, body mass index, Townsend Deprivation Index, family history of prostate cancer, and previous prostate-specific antigen testing.
Results and limitations Mean age at study entry was 56 years, 94% of the men were white, and 1.1% (n=2,311) had a diagnosis of IBD. After a median follow-up of 78 months, men with IBD had an increased risk of PC (adjusted hazards ratio [aHR] = 1.31, 95% Confidence interval [CI] = 1.03-1.67, p = 0.029). Separately analyzing the IBD subtypes of ulcerative colitis (UC) and Crohn’s disease (CD), the association with PC was only among men with the former (UC; aHR = 1.47, 95% CI = 1.11-1.95, p=0.0070), and not the latter (CD; aHR 1.06, 95% CI = 0.63-1.80, p = 0.82). Results are limited by lack of data on frequency of health care interactions.
Conclusions In a large-scale, prospective cohort study, we detected an association between IBD, and UC specifically, with incident PC diagnosis.
Patient summary This study of over 200,000 men in the UK suggests that men with inflammatory bowel disease may be at a higher risk of prostate cancer than the general population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the following NIH grants: NCI R25CA112355, R01CA201358, and NIA T32AG049663.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank is an open access resource. Bona fide researchers can apply to use the UK Biobank dataset by registering and applying at https://www.ukbiobank.ac.uk/register-apply/. All results presented in this manuscript, including the code used to generate them, will be returned to UK Biobank within 6 mo of publication at which point they are made available for researchers to request (subject to UK Biobank approval).
